ARDX Rasio cepet Ardelyx, Inc.

This price chart for Ardelyx, Inc. (ARDX) illustrates the performance of the company developing therapies for renal pathologies, where the liquidity ratio stands at 3.17. The business relies on third-party contractors for the packaging and release of medications while maintaining strict oversight of logistics. High R&D expenditures and patent protection create barriers for competitors under FDA control. The environmental development vector involves the implementation of safe molecule synthesis.

The quick ratio measures a company's ability to instantaneously settle short-term debts using only cash and accounts receivable, excluding slow-moving inventories. By analyzing the current quick liquidity, an investor assesses the financial stability of Ardelyx, Inc. (ARDX) as it scales sales of Xphozah and Ibsrela, where an excess of liquid cash minimizes the risk of cash flow gaps during the process of capturing market share.